Clinical Trials Browser

Completed × INDUSTRY × copanlisib × Clear all

NCT02367040 2025-10-14

CHRONOS-3

Phase 3 Completed

458 enrolled 22 charts

Lymphoma, Non-Hodgkin

NCT05217914 2024-10-24

A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

Recurrence

NCT01660451 2024-07-17

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Phase 2 Completed

227 enrolled 25 charts

Lymphoma, Non-Hodgkin

NCT02369016 2023-11-18

CHRONOS-2

Phase 3 Completed

25 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT03735628 2023-10-06

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors

Phase 1 Completed

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT02342665 2023-01-20

Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL

Phase 1/2 Completed

Lymphoma, Non-Hodgkin

NCT03517956 2022-07-14

ROCOCO

Phase 1 Completed

Neoplasm Metastasis

NCT03498430 2021-05-19

Copanlisib Chinese PK Study

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT03172884 2021-04-28

Study of Copanlisib in Hepatic or Renal Impairment

Phase 1 Completed

30 enrolled 20 charts

Hepatic Insufficiency, Renal Insufficiency

NCT02253420 2020-12-14

COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT02391116 2019-01-04

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Completed

67 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

NCT01411410 2017-10-11

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT00962611 2017-10-06

BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms

NCT02155582 2017-06-16

Copanlisib Pharmacodynamic Study

Phase 1 Completed

Lymphoma, Non-Hodgkin

NCT01392521 2015-04-17

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

Phase 1 Completed

Neoplasms